Treating Patients with SCLC with Driver Mutations
The Oncology Brothers and Eric Singhi, MD, provide clinical insights on the treatment of patients with small cell lung cancer with driver mutations.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
!["This [network meta-analysis] demonstrated for the first time that [anlotinib/benmelstobart plus chemotherapy] is the most efficacious regimen for extending survival in ES-SCLC, highlighting its potential as a preferred first-line treatment option for this patient population," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6934d676a539495d8b2109e4b3762700aa723bf3-1200x873.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"This [network meta-analysis] demonstrated for the first time that [anlotinib/benmelstobart plus chemotherapy] is the most efficacious regimen for extending survival in ES-SCLC, highlighting its potential as a preferred first-line treatment option for this patient population,\" according to the study authors.")
